Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 368

1.

Targeted Delivery of C/EBPα-saRNA by RNA Aptamers Shows Anti-tumor Effects in a Mouse Model of Advanced PDAC.

Yoon S, Huang KW, Andrikakou P, Vasconcelos D, Swiderski P, Reebye V, Sodergren M, Habib N, Rossi JJ.

Mol Ther Nucleic Acids. 2019 Aug 22;18:142-154. doi: 10.1016/j.omtn.2019.08.017. [Epub ahead of print]

2.

Dual Mechanisms of Action of Self-Delivering, Anti-HIV-1 FANA Oligonucleotides as a Potential New Approach to HIV Therapy.

Takahashi M, Li H, Zhou J, Chomchan P, Aishwarya V, Damha MJ, Rossi JJ.

Mol Ther Nucleic Acids. 2019 Sep 6;17:615-625. doi: 10.1016/j.omtn.2019.07.001. Epub 2019 Jul 11.

3.

Identification of Nucleolar Factors During HIV-1 Replication Through Rev Immunoprecipitation and Mass Spectrometry.

Arizala JAC, Chomchan P, Li H, Moore R, Ge H, Ouellet DL, Rossi JJ.

J Vis Exp. 2019 Jun 26;(148). doi: 10.3791/59329.

PMID:
31305524
4.

Triplex Hybridization of siRNA with Bifacial Glycopolymer Nucleic Acid Enables Hepatocyte-Targeted Silencing.

Xia X, Zhou Z, DeSantis C, Rossi JJ, Bong D.

ACS Chem Biol. 2019 Jun 21;14(6):1310-1318. doi: 10.1021/acschembio.9b00273. Epub 2019 Jun 11.

PMID:
31141333
5.

Author Correction: The current state and future directions of RNAi-based therapeutics.

Setten RL, Rossi JJ, Han SP.

Nat Rev Drug Discov. 2019 Apr 24. doi: 10.1038/s41573-019-0027-2. [Epub ahead of print]

PMID:
31019276
6.

Publisher Correction: The current state and future directions of RNAi-based therapeutics.

Setten RL, Rossi JJ, Han SP.

Nat Rev Drug Discov. 2019 Mar 18. doi: 10.1038/s41573-019-0023-6. [Epub ahead of print]

PMID:
30886427
7.

Anti-inflammatory Activity of MTL-CEBPA, a Small Activating RNA Drug, in LPS-Stimulated Monocytes and Humanized Mice.

Zhou J, Li H, Xia X, Herrera A, Pollock N, Reebye V, Sodergren MH, Dorman S, Littman BH, Doogan D, Huang KW, Habib R, Blakey D, Habib NA, Rossi JJ.

Mol Ther. 2019 May 8;27(5):999-1016. doi: 10.1016/j.ymthe.2019.02.018. Epub 2019 Feb 26.

8.

The current state and future directions of RNAi-based therapeutics.

Setten RL, Rossi JJ, Han SP.

Nat Rev Drug Discov. 2019 Jun;18(6):421-446. doi: 10.1038/s41573-019-0017-4. Review. Erratum in: Nat Rev Drug Discov. 2019 Mar 18;:. Nat Rev Drug Discov. 2019 Apr 24;:.

PMID:
30846871
9.

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies.

Xia X, Li H, Satheesan S, Zhou J, Rossi JJ.

J Vis Exp. 2019 Jan 7;(143). doi: 10.3791/58255.

10.

An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFRα Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma.

Yoon S, Wu X, Armstrong B, Habib N, Rossi JJ.

Mol Ther Nucleic Acids. 2019 Mar 1;14:131-141. doi: 10.1016/j.omtn.2018.11.012. Epub 2018 Dec 1.

11.

Targeted Molecular Imaging Using Aptamers in Cancer.

Yoon S, Rossi JJ.

Pharmaceuticals (Basel). 2018 Jul 19;11(3). pii: E71. doi: 10.3390/ph11030071. Review.

12.

Aptamers: Uptake mechanisms and intracellular applications.

Yoon S, Rossi JJ.

Adv Drug Deliv Rev. 2018 Sep;134:22-35. doi: 10.1016/j.addr.2018.07.003. Epub 2018 Jul 6. Review.

PMID:
29981799
13.

Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation.

Chen RW, Palmer JM, Tomassetti S, Popplewell LL, Alluin J, Chomchan P, Nademanee AP, Siddiqi T, Tsai NC, Chen L, Zuo F, Abary R, Cai JL, Herrera AF, Rossi JJ, Rosen ST, Forman SJ, Kwak LW, Holmberg LA.

J Hematol Oncol. 2018 Jun 28;11(1):87. doi: 10.1186/s13045-018-0631-3.

14.

Development of MTL-CEBPA: Small Activating RNA Drug for Hepatocellular Carcinoma.

Setten RL, Lightfoot HL, Habib NA, Rossi JJ.

Curr Pharm Biotechnol. 2018;19(8):611-621. doi: 10.2174/1389201019666180611093428. Review.

15.

Therapeutic Potential of Small Activating RNAs (saRNAs) in Human Cancers.

Yoon S, Rossi JJ.

Curr Pharm Biotechnol. 2018;19(8):604-610. doi: 10.2174/1389201019666180528084059. Review.

16.

Nucleolar Localization of HIV-1 Rev Is Required, Yet Insufficient for Production of Infectious Viral Particles.

Arizala JAC, Takahashi M, Burnett JC, Ouellet DL, Li H, Rossi JJ.

AIDS Res Hum Retroviruses. 2018 Nov;34(11):961-981. doi: 10.1089/AID.2017.0306. Epub 2018 Jul 5.

17.

Receptor-targeted aptamer-siRNA conjugate-directed transcriptional regulation of HIV-1.

Zhou J, Lazar D, Li H, Xia X, Satheesan S, Charlins P, O'Mealy D, Akkina R, Saayman S, Weinberg MS, Rossi JJ, Morris KV.

Theranostics. 2018 Feb 7;8(6):1575-1590. doi: 10.7150/thno.23085. eCollection 2018.

18.

Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer.

Reebye V, Huang KW, Lin V, Jarvis S, Cutilas P, Dorman S, Ciriello S, Andrikakou P, Voutila J, Saetrom P, Mintz PJ, Reccia I, Rossi JJ, Huber H, Habib R, Kostomitsopoulos N, Blakey DC, Habib NA.

Oncogene. 2018 Jun;37(24):3216-3228. doi: 10.1038/s41388-018-0126-2. Epub 2018 Mar 7.

19.

RAFTing Towards the Shore of Nanotherapeutic.

Xia X, Rossi JJ.

Curr Drug Deliv. 2018;15(8):1084-1086. doi: 10.2174/1567201815666180220100733. No abstract available.

PMID:
29468969
20.

HIV Replication and Latency in a Humanized NSG Mouse Model during Suppressive Oral Combinational Antiretroviral Therapy.

Satheesan S, Li H, Burnett JC, Takahashi M, Li S, Wu SX, Synold TW, Rossi JJ, Zhou J.

J Virol. 2018 Mar 14;92(7). pii: e02118-17. doi: 10.1128/JVI.02118-17. Print 2018 Apr 1.

21.

Current Advances in Aptamers for Cancer Diagnosis and Therapy.

Hori SI, Herrera A, Rossi JJ, Zhou J.

Cancers (Basel). 2018 Jan 3;10(1). pii: E9. doi: 10.3390/cancers10010009. Review.

22.

Incorporation of aptamers in the terminal loop of shRNAs yields an effective and novel combinatorial targeting strategy.

Pang KM, Castanotto D, Li H, Scherer L, Rossi JJ.

Nucleic Acids Res. 2018 Jan 9;46(1):e6. doi: 10.1093/nar/gkx980.

23.

Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer.

Voutila J, Reebye V, Roberts TC, Protopapa P, Andrikakou P, Blakey DC, Habib R, Huber H, Saetrom P, Rossi JJ, Habib NA.

Mol Ther. 2017 Dec 6;25(12):2705-2714. doi: 10.1016/j.ymthe.2017.07.018. Epub 2017 Aug 4.

24.

Emerging cancer-specific therapeutic aptamers.

Yoon S, Rossi JJ.

Curr Opin Oncol. 2017 Sep;29(5):366-374. doi: 10.1097/CCO.0000000000000389. Review.

25.

Treatment of Pancreatic Cancer by Aptamer Conjugated C/EBPα-saRNA.

Yoon S, Rossi JJ.

Adv Exp Med Biol. 2017;983:173-188. doi: 10.1007/978-981-10-4310-9_12.

PMID:
28639199
26.

Molecular mechanisms of Dicer: endonuclease and enzymatic activity.

Song MS, Rossi JJ.

Biochem J. 2017 May 4;474(10):1603-1618. doi: 10.1042/BCJ20160759. Review.

27.

Blind SELEX Approach Identifies RNA Aptamers That Regulate EMT and Inhibit Metastasis.

Yoon S, Armstrong B, Habib N, Rossi JJ.

Mol Cancer Res. 2017 Jul;15(7):811-820. doi: 10.1158/1541-7786.MCR-16-0462. Epub 2017 Apr 10.

28.

Aptamer-Drug Conjugates of Active Metabolites of Nucleoside Analogs and Cytotoxic Agents Inhibit Pancreatic Tumor Cell Growth.

Yoon S, Huang KW, Reebye V, Spalding D, Przytycka TM, Wang Y, Swiderski P, Li L, Armstrong B, Reccia I, Zacharoulis D, Dimas K, Kusano T, Shively J, Habib N, Rossi JJ.

Mol Ther Nucleic Acids. 2017 Mar 17;6:80-88. doi: 10.1016/j.omtn.2016.11.008. Epub 2016 Dec 10.

29.

Future strategies for the discovery of therapeutic aptamers.

Yoon S, Rossi JJ.

Expert Opin Drug Discov. 2017 Apr;12(4):317-319. doi: 10.1080/17460441.2017.1290077. Epub 2017 Feb 15. No abstract available.

30.

The Experiment Was a Success: Celebrating a Milestone in MTNA's Existence.

Rossi JJ.

Mol Ther. 2017 Feb 1;25(2):303. doi: 10.1016/j.ymthe.2017.01.003. Epub 2017 Jan 18. No abstract available.

31.

High throughput sequencing analysis of RNA libraries reveals the influences of initial library and PCR methods on SELEX efficiency.

Takahashi M, Wu X, Ho M, Chomchan P, Rossi JJ, Burnett JC, Zhou J.

Sci Rep. 2016 Sep 22;6:33697. doi: 10.1038/srep33697.

32.

AptaTRACE Elucidates RNA Sequence-Structure Motifs from Selection Trends in HT-SELEX Experiments.

Dao P, Hoinka J, Takahashi M, Zhou J, Ho M, Wang Y, Costa F, Rossi JJ, Backofen R, Burnett J, Przytycka TM.

Cell Syst. 2016 Jul;3(1):62-70. doi: 10.1016/j.cels.2016.07.003.

33.

Mastering Dendrimer Self-Assembly for Efficient siRNA Delivery: From Conceptual Design to In Vivo Efficient Gene Silencing.

Chen C, Posocco P, Liu X, Cheng Q, Laurini E, Zhou J, Liu C, Wang Y, Tang J, Col VD, Yu T, Giorgio S, Fermeglia M, Qu F, Liang Z, Rossi JJ, Liu M, Rocchi P, Pricl S, Peng L.

Small. 2016 Jul;12(27):3667-76. doi: 10.1002/smll.201503866. Epub 2016 May 31.

34.

Targeted Delivery of C/EBPα -saRNA by Pancreatic Ductal Adenocarcinoma-specific RNA Aptamers Inhibits Tumor Growth In Vivo.

Yoon S, Huang KW, Reebye V, Mintz P, Tien YW, Lai HS, Sætrom P, Reccia I, Swiderski P, Armstrong B, Jozwiak A, Spalding D, Jiao L, Habib N, Rossi JJ.

Mol Ther. 2016 Jun;24(6):1106-1116. doi: 10.1038/mt.2016.60. Epub 2016 Mar 17. Erratum in: Mol Ther. 2016 Dec;24(12):2131-2132.

35.

Evolution of Cell-Type-Specific RNA Aptamers Via Live Cell-Based SELEX.

Zhou J, Rossi JJ.

Methods Mol Biol. 2016;1421:191-214. doi: 10.1007/978-1-4939-3591-8_16.

PMID:
26965267
36.

Downregulation of TLX induces TET3 expression and inhibits glioblastoma stem cell self-renewal and tumorigenesis.

Cui Q, Yang S, Ye P, Tian E, Sun G, Zhou J, Sun G, Liu X, Chen C, Murai K, Zhao C, Azizian KT, Yang L, Warden C, Wu X, D'Apuzzo M, Brown C, Badie B, Peng L, Riggs AD, Rossi JJ, Shi Y.

Nat Commun. 2016 Feb 3;7:10637. doi: 10.1038/ncomms10637.

37.

Design of Effective Primary MicroRNA Mimics With Different Basal Stem Conformations.

van den Berg FT, Rossi JJ, Arbuthnot P, Weinberg MS.

Mol Ther Nucleic Acids. 2016 Jan 12;5:e278. doi: 10.1038/mtna.2015.53.

38.

RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise?

Bobbin ML, Rossi JJ.

Annu Rev Pharmacol Toxicol. 2016;56:103-22. doi: 10.1146/annurev-pharmtox-010715-103633. Review.

PMID:
26738473
39.

LGIT In Vitro Latency Model in Primary and T Cell Lines to Test HIV-1 Reactivation Compounds.

Jung U, Takahashi M, Rossi JJ, Burnett JC.

Methods Mol Biol. 2016;1354:255-64. doi: 10.1007/978-1-4939-3046-3_17.

PMID:
26714717
40.

Progress toward curing HIV infection with hematopoietic cell transplantation.

Petz LD, Burnett JC, Li H, Li S, Tonai R, Bakalinskaya M, Shpall EJ, Armitage S, Kurtzberg J, Regan DM, Clark P, Querol S, Gutman JA, Spellman SR, Gragert L, Rossi JJ.

Stem Cells Cloning. 2015 Jul 28;8:109-16. doi: 10.2147/SCCAA.S56050. eCollection 2015. Review.

41.

Preclinical Assessment of Mutant Human TRIM5α as an Anti-HIV-1 Transgene.

Jung U, Urak K, Veillette M, Nepveu-Traversy MÉ, Pham QT, Hamel S, Rossi JJ, Berthoux L.

Hum Gene Ther. 2015 Oct;26(10):664-79. doi: 10.1089/hum.2015.059. Epub 2015 Aug 6.

42.

RNA interference approaches for treatment of HIV-1 infection.

Bobbin ML, Burnett JC, Rossi JJ.

Genome Med. 2015 May 28;7(1):50. doi: 10.1186/s13073-015-0174-y. eCollection 2015.

43.

Piwi-Interacting RNAs (piRNAs) Are Dysregulated in Renal Cell Carcinoma and Associated with Tumor Metastasis and Cancer-Specific Survival.

Li Y, Wu X, Gao H, Jin JM, Li AX, Kim YS, Pal SK, Nelson RA, Lau CM, Guo C, Mu B, Wang J, Wang F, Wang J, Zhao Y, Chen W, Rossi JJ, Weiss LM, Wu H.

Mol Med. 2015 May 13;21:381-8. doi: 10.2119/molmed.2014.00203.

44.

Methods for assembling B-cell lymphoma specific and internalizing aptamer-siRNA nanoparticles via the sticky bridge.

Zhou J, Rossi JJ, Shum KT.

Methods Mol Biol. 2015;1297:169-85. doi: 10.1007/978-1-4939-2562-9_12.

PMID:
25896003
45.

Twenty-five plus years of an RNA addiction.

Rossi JJ.

RNA. 2015 Apr;21(4):721-2. doi: 10.1261/rna.050120.115. No abstract available.

46.

RNA-based TWIST1 inhibition via dendrimer complex to reduce breast cancer cell metastasis.

Finlay J, Roberts CM, Lowe G, Loeza J, Rossi JJ, Glackin CA.

Biomed Res Int. 2015;2015:382745. doi: 10.1155/2015/382745. Epub 2015 Feb 11.

47.

Aptamer-siRNA chimeras for HIV.

Takahashi M, Burnett JC, Rossi JJ.

Adv Exp Med Biol. 2015;848:211-34. doi: 10.1007/978-1-4939-2432-5_11. Review.

PMID:
25757623
48.

Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity.

Zhou J, Satheesan S, Li H, Weinberg MS, Morris KV, Burnett JC, Rossi JJ.

Chem Biol. 2015 Mar 19;22(3):379-90. doi: 10.1016/j.chembiol.2015.01.005. Epub 2015 Mar 5.

49.

HIV-1 RRE RNA acts as an RNA silencing suppressor by competing with TRBP-bound siRNAs.

Daniels SM, Sinck L, Ward NJ, Melendez-Peña CE, Scarborough RJ, Azar I, Rance E, Daher A, Pang KM, Rossi JJ, Gatignol A.

RNA Biol. 2015;12(2):123-35. doi: 10.1080/15476286.2015.1014759.

50.

Noncoding oligonucleotides: the belle of the ball in gene therapy.

Shum KT, Rossi JJ.

Adv Genet. 2015;89:153-177. doi: 10.1016/bs.adgen.2014.10.004. Epub 2014 Dec 4.

PMID:
25620011

Supplemental Content

Loading ...
Support Center